arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Schrodinger, Inc.

SDGR
$18.16 ▲ +0.35 (+1.97%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
7 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Schrodinger, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield
Revenue Growth 23.3%
Op. Margin -65.2%
ROIC -46.3%
FCF / Share $0.17
Trailing P/E
Price / Book 3.7x
FCF Yield 0.9%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$255.87M
↑ +23.3%
Net Income Profit after all expenses
$-103.27M
↑ +44.8%
Operating Margin Operating profit as % of sales
-65.2%
↑ +35.3% 4th
FCF / Share Free cash flow per share
$0.17
↑ +107.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
18
Returns
24
Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 29 quarters